23andMe, Pfizer, Inc. and the on the genetics of the autoimmune disease known as lupus.
The aim is to quickly enroll 5,000 people with the disease, which affects about 1.5 million people in the United States alone.
“The ability to effectively personalize treatments for lupus patients is limited, due in large part to our incomplete understanding of the disease,” said 23andMe CEO and co-founder Anne Wojcicki. “We hope to change that by studying human genetics alongside environmental and health history factors to ultimately help inform better treatment options for lupus patients.”
Recruitment for the study begins this month, which is also Lupus Awareness Month.
The disease is characterized by the body’s immune system attacking normal, healthy tissues almost anywhere in the body. People with lupus might have symptoms that include inflammation of the joints, or skin rashes, sores or damage to the kidneys, or heart or lungs.
While there is no cure for the disease and it isn’t very well understood, researchers know some factors linked to the disease. They know that there are both environmental and genetic factors involved, and hormones also play a role.
The research to be lead by 23andMe will focus on genetic factors, but it will also incorporate data from participants’ medical records and look at how the disease progresses over time. The hope is that this research will uncover some of the genetic causes for lupus that could indicate onset of the disease, how it progresses and how patients respond differently to different treatments.
“Pfizer is committed to bringing forward new treatments for patients suffering from lupus,” said Belen Carrillo-Rivas, D.Phil., Head of Research & Development Innovation Projects, BioTherapeutics Research & Development, Pfizer. “By enhancing our understanding of the underlying biology of the disease, we hope to better support our clinical research activities and development programs.”
For the lupus study, 23andMe will recruit new participants as well as conduct outreach to existing customers, who once determined eligible, will be required to provide consent to participate in this new project. Recruitment of eligible study participants is expected to be completed by mid 2016.
For more information, including eligibility requirements for joining the study, please visit https://www.23andme.com/lupus/.